Skip to main content

Neurotrack Test Validation

Unknown status

This study will validate Neurotrack's visual paired comparison task to determine whether this task is associated with markers of brain pathology indicating very early Alzheimer's disease.

Minimum Age Maximum Age Gender Healthy Volunteers
60 Years 85 Years Both Yes
October 2015
December 2017
80

  • Clinical diagnosis based on recent (within 1 year) consensus meeting and neuropsychological test scores
  • Cognitively normal participants: cognitively normal based on Mini-Mental State Examination (MMSE), Clinical Dementia Rating (CDR), and GDS scores
  • Amnestic mild cognitive impairment (aMCI) participants: diagnosis of aMCI, based on MMSE, CDR, and GDS scores
  • Normal or corrected-to-normal vision and hearing (able to see images on computer screen and hear auditory events delivered through the computer speaker)

  • Significant history of mental illness; clinical depression not medically controlled; drug or alcohol abuse
  • Severe trauma preventing normal use of dominant hand (needed to move the computer mouse)
  • Other neurologic conditions (such as stroke), learning disability, or vision problems that prevent viewing a computer screen at a normal distance, including legal blindness, detached retinas, occlusive cataracts
  • Pacemaker, aneurysm clip, cochlear implant, pulse oximeter, EKG lead, tattoos, or other metal/foreign objects in body or face that preclude MRI
  • Lack of capacity to give informed consent and lack of authorized representative to provide consent
  • Pregnant, breastfeeding, or planning to have a baby

Neurotrack is a test being developed to detect cognitive deficits using safe, noninvasive technology. In this study, participants who are cognitively normal or have amnestic mild cognitive impairment will take the Neurotrack visual paired-comparison task and undergo an MRI scan.

Participants are individuals who are participating in ongoing research at the New York University Alzheimer's Disease Center (ADC) and have received the standard ADC clinical evaluation within the past year. The current protocol is strictly a research study, and there will be no "standard care" provided. Participants will attend two separate sessions, the first to screen for eligibility and to administer cognitive tests and the second to undergo an MRI, which will be used to derive brain pathology measurements.

Data from this study will be correlated with data from a parallel study, designed to validate a larger group of new cognitive tasks by correlating test performance with a broader array of biomarkers of Alzheimer's disease.

Name City State Zip Status Primary Contact
NYU Langone Medical Center
New York New York 10016 Recruiting Steven Ferris
212-263-5703
steven.ferris@nyumc.org

New York University School of Medicine

  • NeuroTrack Technologies, Inc.

NCT02608021

Neurotrack Test Validation Protocol